Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches

BACKGROUND: Indacaterol is a once-daily long-acting inhaled β(2)-agonist indicated for maintenance treatment of moderate-to-severe chronic obstructive pulmonary disease (COPD). The large inter-patient and inter-study variability in forced expiratory volume in 1 second (FEV(1)) with bronchodilators m...

Descripción completa

Detalles Bibliográficos
Autores principales: Renard, Didier, Looby, Michael, Kramer, Benjamin, Lawrence, David, Morris, David, Stanski, Donald R
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3102616/
https://www.ncbi.nlm.nih.gov/pubmed/21518459
http://dx.doi.org/10.1186/1465-9921-12-54

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3102616/
https://www.ncbi.nlm.nih.gov/pubmed/21518459
http://dx.doi.org/10.1186/1465-9921-12-54

Ejemplares similares